Molecular mechanism underlying B19 virus inactivation and comparison to other parvoviruses

Transfusion

Volumn 47, Issue 10, 2007, Pages 1765-1774

  Mani, Bernhard ^b   Gerber, Marco ^b   Lieby, Patricia ^b   Boschetti, Nicola ^b   Kempf, Christoph ^b   Ros, Carlos ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; NUCLEASE; PROTEIN VP1; PROTEIN VP2; VIRUS DNA;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DNA HYBRIDIZATION; DNA INTEGRATION; HEAT; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MITOCHONDRIAL DNA DEPLETION; MOLECULAR MECHANICS; NONHUMAN; PARVOVIRUS; PH; QUANTITATIVE ANALYSIS; TARGET CELL; VIRION; VIRUS ADSORPTION; VIRUS CAPSID; VIRUS INACTIVATION; VIRUS INFECTIVITY; VIRUS PARTICLE;

BLOOD TRANSFUSION; CAPSID PROTEINS; CELL LINE; DNA PRIMERS; DNA, VIRAL; ERYTHEMA INFECTIOSUM; FLOW CYTOMETRY; HEAT; HUMANS; HYDROGEN-ION CONCENTRATION; PARVOVIRUS B19, HUMAN; POLYMERASE CHAIN REACTION; VIRUS INACTIVATION;

EID: 34548785009     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01393.x     Document Type: Article

References (41)

1. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002 15 : 485 505.
2. Prowse C, Ludlam CA, Yap PL. Human parvovirus B19 and blood products. Vox Sang 1997 72 : 1 10.
3. Candotti D, Etiz N, Parsyan A, Allain JP. Identification and characterization of persistent human erythrovirus infection in blood donor samples. J Virol 2004 78 : 12169 78.
4. Thomas I, Di Giambattista M, Gerard C, et al. Prevalence of human erythrovirus B19 DNA in healthy Belgian blood donors and correlation with specific antibodies against structural and non-structural viral proteins. Vox Sang 2003 84 : 300 7.
5. Tsujimura M, Matsushita K, Shiraki H, Sato H, Okochi K, Maeda Y. Human parvovirus B19 infection in blood donors. Vox Sang 1995 69 : 206 12.
6. Wakamatsu C, Takakura F, Kojima E, et al. Screening of blood donors for human parvovirus B19 and characterization of the results. Vox Sang 1999 76 : 14 21.
7. Yoto Y, Kudoh T, Haseyama K, et al. Incidence of human parvovirus B19 DNA detection in blood donors. Br J Haematol 1995 91 : 1017 8.
8. Saldanha J, Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 1996 93 : 714 9.
9. Schmidt I, Blumel J, Seitz H, Willkommen H, Lower J. Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sang 2001 81 : 228 35.
10. Zaaijer HL, Koppelman MH, Farrington CP. Parvovirus B19 viraemia in Dutch blood donors. Epidemiol Infect 2004 132 : 1161 6.
11. Plentz A, Hahn J, Knoll A, Holler E, Jilg W, Modrow S. Exposure of hematologic patients to parvovirus B19 as a contaminant of blood cell preparations and blood products. Transfusion 2005 45 : 1811 5.
12. Schneider B, Becker M, Brackmann HH, Eis-Hubinger AM. Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2. Thromb Haemost 2004 92 : 838 45.
13. Blumel J, Schmidt I, Effenberger W, et al. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 2002 42 : 1473 81.
14. Hino M, Ishiko O, Honda KI, et al. Transmission of symptomatic parvovirus B19 infection by fibrin sealant used during surgery. Br J Haematol 2000 108 : 194 5.
15. Matsui H, Sugimoto M, Tsuji S, Shima M, Giddings J, Yoshioka A. Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate. J Pediatr Hematol Oncol 1999 21 : 74 6.
16. Santagostino E, Mannucci PM, Gringeri A, et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Transfusion 1997 37 : 517 22.
17. Laub R, Strengers P. Parvoviruses and blood products. Pathol Biol (Paris) 2002 50 : 339 48.
18. Blumel J, Schmidt I, Willkommen H, Lower J. Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 2002 42 : 1011 8.
19. Miyagawa E, Yoshida T, Takahashi H, et al. Infection of the erythroid cell line, KU812Ep6 with human parvovirus B19 and its application to titration of B19 infectivity. J Virol Methods 1999 83 : 45 54.
20. Prikhod'ko GG, Vasilyeva I, Reyes H, et al. Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies. Transfusion 2005 45 : 1011 9.
21. Yunoki M, Tsujikawa M, Urayama T, et al. Heat sensitivity of human parvovirus B19 [published erratum appears in Vox Sang 2003;85:67-8]. Vox Sang 2003 84 : 164 9.
22. Blumel J, Eis-Hubinger AM, Stuhler A, Bonsch C, Gessner M, Lower J. Characterization of parvovirus B19 genotype 2 in KU812Ep6 cells. J Virol 2005 79 : 14197 206.
23. Boschetti N, Niederhauser I, Kempf C, et al. Different susceptibility of B19 virus and mice minute virus to low pH treatment. Transfusion 2004 44 : 1079 86.
24. Caillet-Fauquet P, Di Giambattista M, Draps ML, et al. Continuous-flow UVC irradiation: a new, effective, protein activity-preserving system for inactivating bacteria and viruses, including erythrovirus B19. J Virol Methods 2004 118 : 131 9.
25. Sugawara H, Motokawa R, Abe H, et al. Inactivation of parvovirus B19 in coagulation factor concentrates by UVC radiation: assessment by an in vitro infectivity assay using CFU-E derived from peripheral blood CD34+ cells. Transfusion 2001 41 : 456 61.
26. Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005 45 : 580 90.
27. Boschetti N, Wyss K, Mischler A, Hostettler T, Kempf C. Stability of minute virus of mice against temperature and sodium hydroxide. Biologicals 2003 31 : 181 5.
28. Ros C, Baltzer C, Mani B, Kempf C. Parvovirus uncoating in vitro reveals a mechanism of DNA release without capsid disassembly and striking differences in encapsidated DNA stability. Virology 2006 345 : 137 47.
29. Hattori S, Yunoki M, Tsujikawa M, et al. Variability of parvovirus B19 to inactivation by liquid heating in plasma products. Vox Sang 2007 92 : 121 4.
30. Cavalli-Sforza L. Biometrie: Grundzüge biologisch-medizinischer Statistik. Stuttgart : G. Fischer Verlag 1974.
31. Gigler A, Dorsch S, Hemauer A, et al. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol 1999 73 : 1974 9.
32. Kasermann F, Kempf C, Boschetti N. Strengths and limitations of the model virus concept. PDA J Pharm Sci Technol 2004 58 : 244 9.
33. Bleker S, Pawlita M, Kleinschmidt JA. Impact of capsid conformation and Rep-capsid interactions on adeno-associated virus type 2 genome packaging. J Virol 2006 80 : 810 20.
34. Cotmore SF, D'abramo AM Jr., Ticknor CM, Tattersall P. Controlled conformational transitions in the MVM virion expose the VP1 N-terminus and viral genome without particle disassembly. Virology 1999 254 : 169 81.
35. Mani B, Baltzer C, Valle N, et al. Low pH-dependent endosomal processing of the incoming parvovirus minute virus of mice virion leads to externalization of the VP1 N-terminal sequence (N-VP1), N-VP2 cleavage, and uncoating of the full-length genome. J Virol 2006 80 : 1015 24.
36. Ros C, Gerber M, Kempf C. Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. J Virol 2006 80 : 12017 24.
37. Zipris D, Lien E, Nair A, et al. TLR9-signaling pathways are involved in kilham rat virus-induced autoimmune diabetes in the biobreeding diabetes-resistant rat. J Immunol 2007 178 : 693 701.
38. Norbeck O, Tolfvenstam T, Shields LE, Westgren M, Broliden K. Parvovirus B19 capsid protein VP2 inhibits hematopoiesis in vitro and in vivo: implications for therapeutic use. Exp Hematol 2004 32 : 1082 7.
39. Lehmann HW, Von Landenberg P, Modrow S. Parvovirus B19 infection and autoimmune disease. Autoimmun Rev 2003 2 : 218 23.
40. Von Landenberg P, Lehmann HW, Knoll A, Dorsch S, Modrow S. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum 2003 48 : 1939 47.
41. Lu J, Zhi N, Wong S, Brown KE. Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. J Infect Dis 2006 193 : 582 90.